Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
5 papers
Recent·Most cited
C. Larrue, S. Mouche, P. Angelino, M. Sajot, R. Birsen, F. Vergez, C. Recher, V. Mansat-De Mas, Q. Gu, J. Xu, P. Tsantoulis, J.-E. Sarry, J. Tamburini
The paper identifies ferritinophagy as a therapeutic target in quiescent leukemic stem cells, showing that inhibiting NCOA4 reduces leukemia.
bioRxiv · Dec 18, 2023 · PreprintCancer Biology
R. Marone, E. Landmann, A. Devaux, R. Lepore, D. Seyres, J. Zuin, T. Burgold, C. Engdahl, G. Capoferri, A. DellAglio, C. Larrue, F. Simonetta, J. Rositzka, M. Rhiel, G. Andrieux, , L. T. Jeker
This paper shows that epitope-engineered human hematopoietic stem cells are protected from CD123-targeted immunotherapy while maintaining functionality, offering a strategy for tumor-selective therapy.
bioRxiv · Jul 11, 2023Bioengineering
S. Lin, C. Larrue, B. K. A. Seong, N. V. Dharia, M. Kuljanin, C. Wechsler, G. Kugener, A. Robichaud, A. Conway, T. N. Mashaka, S. Mouche, B. Adane, J. Ryan, J. D. Mancias, S. T. Younger, , K. Stegmaier
This study identifies novel therapeutic targets for AML using an in vivo CRISPR screening platform, revealing SLC5A3 as a metabolic vulnerability and MARCH5 as an apoptosis regulator.
bioRxiv · Dec 28, 2020Cancer Biology
C. Bosc, N. Gadaud, A. Bousard, M. Sabatier, G. Cognet, E. Saland, T. Farge, E. Boet, M. Gotanegre, N. Aroua, P.-L. Mouchel, C. Larrue, L. Jarrou, F. Rambow, F. Cabon, , J.-E. Sarry
This study identifies mitochondrial determinants of response and resistance to venetoclax plus cytarabine therapy in AML, showing that OxPHOS is a predictive marker and that targeting ETCI improves outcomes.
bioRxiv · Aug 17, 2020 · PreprintCancer Biology
C. Larrue, N. Guiraud, P.-L. Mouchel, M. Dubois, T. Farge, M. Gotanegre, C. Bosc, E. Saland, M.-L. Travers-Nicolau, M. Sabatier, N. Serhan, A. Sahal, E. Boet, S. Mouche, Q. Heydt, , J.-E. Sarry
The paper identifies the ADM-CALCRL axis as a driver of drug-tolerant AML cells that persist after chemotherapy and proposes it as a therapeutic target to prevent relapse.
bioRxiv · Aug 17, 2020Cancer Biology